Anti-inflammatory effect of mesenchymal stem cells on hepatocellular carcinoma in the xenograft mice model

Saieh Hajighasemlou,Mohsen Nikbakht,Saeedreza Pakzad,Abdolnaser Azadbakht,Samad Muhammadnejad,Milad Mirmoghtadaei,Safoora Gharibzadeh,Iman Seyhoun,Javad Verdi
DOI: https://doi.org/10.1002/vms3.886
Abstract:Background: Hepatocellular carcinoma (HCC) is the fifth most diagnosed cancer and the second leading cause of cancer-related deaths worldwide. Sorafenib is the standard treatment used in the advanced stages of HCC. Cell therapy with mesenchymal stem cells (MSCs)-based cell therapy has proven effective in immune regulation and tumour growth inhibition. Objectives: In this study, we investigated the anti-inflammatory effect of MSCs on HCC xenografts. Methods: Human HepG2 cell lines were subcutaneously implanted into the flank of 12 nude mice, divided into three groups: the control group, the IV group (intravenous MSCs injection) and the local group (local MSCs injection). Mice were sacrificed 6 weeks after tumour implantation, and tumours were resected entirety. Quantitative real-time polymerase chain reaction (qRT-PCR) measured the gene expression of inflammatory markers, including tumour necrosis factor-α (TNF-α), interleukin (IL)-1α and IL-10. Aspartate transaminase (AST), alanine transaminase (ALT) and urea levels were measured using spectrophotometry to ensure the safety of MSC therapy. Results: Gene expressions for all three inflammatory markers were reduced in both MSCs groups compared to the control group. AST, ALT and urea levels remained in normal ranges. Conclusions: MSC therapy can reduce inflammation in HCC xenograft mouse models.
What problem does this paper attempt to address?